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A B S T R A C T
The aim of this study was to evaluate primary DNA damage and the dynamics of the repair of radiotherapy-induced
DNA lesions in non-target cells of cancer patients. This study included patients diagnosed with different solid tumors
who received radiotherapy. The levels of DNA damage were evaluated using the alkaline comet assay on peripheral blood
leukocytes. Altogether four blood samples per patient were collected: before and after receiving the first dose of radiother-
apy, in the middle of radiotherapy cycle, and after the last dose of radiotherapy. The results indicate that after the first ra-
diation dose significantly increased levels of DNA damage were recorded in almost all cancer patients compared to their
baseline values. Specific patterns of DNA damage were recorded in samples analyzed in the middle of radiotherapy and
after receiving the last dose, indicating the possibility of adaptive response in some patients. Our results indicate that
persistence of post-irradiation damage in peripheral blood leukocytes (and possibly in other non-target cells) of cancer
patients that are strong determinants for the secondary cancer risk. Moreover, the alkaline comet assay was confirmed as
a rapid and sensitive assay for the assessment of genome damage after in vivo irradiation.
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Introduction
The recent literature from the field of clinical oncol-
ogy and radiotherapy still does not explain sufficiently
the question of the ratio of damages to non-tumor cells
and tissues after radiation treatment. Ionizing radiation
is a proven mutagen that, besides damaging tumor tis-
sue, also caused genome damage in other cells. Genome
damage caused by radiation or other mutagens is the
most frequently monitored in peripheral blood lympho-
cytes1. In the lymphocytes of oncological patients treated
with radiotherapy it is extremely important to study the
processes of DNA repair as well as qualitative and quan-
titative changes in various cytogenetic biomarkers. All
these factors may indicate the individual (over) sensitiv-
ity to radiotherapy and a potential risk for the appear-
ance of secondary tumors. Research has undoubtedly
shown that individual cytogenetic and molecular-biologi-
cal tests are useful indicators or biomarkers, applicable
for short-term2–5 or long-term cytogenetic monitoring in
oncological patients6–8. The results of previous cytoge-
netic studies indicate the increase of the frequency of un-
stable chromosome aberrations and the increase in the
number of micronuclei in peripheral blood lymphocytes
in oncological patients treated with radiation9,10. Fur-
thermore, the results of sensitive molecular-biological
tests, such as the comet assay, indicate the increase in
the level of primary DNA damage in peripheral blood
lymphocytes of the patients with malignant tumors in
comparison with healthy population3,11–13.
The alkaline comet assay has become popular way of
detecting a variety of types of DNA damage during last
decade and its usage in clinical practice also increases
rapidly14,15. The basic principle of the comet assay is the
migration of DNA in an agarose matrix under electro-
phoretic conditions. When viewed under microscope, a
cell has the appearance of a comet, with a head (the nu-
clear region) and a tail containing DNA fragments or
strands migrating in the direction of anode. Among them
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various versions of the assay, the alkaline (pH of the un-
winding and electrophoresis buffer >13) method enables
the detection of a broad spectrum of DNA damage. It can
detect double- and single-strand breaks, alkali-labile sites
and single-strand breaks associated with incomplete ex-
cision repair. Under certain conditions, the assay can also
detect DNA-DNA and DNA-protein cross linking, as well
as apoptotic and necrotic cells16–18.
In the present study the alkaline comet assay was ap-
plied to survey the levels of primary DNA damage in pe-
ripheral blood leukocytes collected from 10 cancer pa-
tients who were post-surgically treated with primary or
adjuvant radiotherapy. The objective of our investigation
was also to study the dynamics of the repair of radiother-
apy-induced DNA lesions in non-target cells and to esti-
mate the potential value of the alkaline comet assay as a
possible predictor of response to treatment.
Patients and Methods
Patient population
Study participants were recruited at The University
Hospital for Tumors (Zagreb, Croatia), from a group of
cancer patients who had not previously been treated with
cytotoxic drugs or radiotherapy. The research included
ten patients (four female and six male; aged 35–79 years)
with solid tumors of the head and neck, prostate, uterus,
lungs, breasts, brains and testes. Detailed patient data is
quoted in Table 1.
In our study two patients were diagnosed with an in-
vasive breast carcinoma G2, hormone receptor positive,
HER2/neu negative, T2N1M0 (stage II). Conceptually,
the adjuvant treatment of breast cancer (except lobular
carcinoma [LCIS]) includes the treatment of local disease
with surgery, radiation therapy (RT), or both, and the
treatment of systemic disease with cytotoxic chemotherapy
or hormonal therapy19,20. After radical operation – mas-
tectomy and ipsilateral lymphnode dissection the pa-
tients wish was to be treated with radiotherapy and sub-
sequent hormonotherapy with tamoxifen. Radiotherapy
was done with direct field to the chest whole and supra-
clavicular region with the total tumor dose of 45 Gy in 18
daily fractions (Figure 1.).
Two patients had a squamous cell carcinoma T2 N1
M0 (Stage III) of the oropharynx, which is extremely rich
in lymphatics. Postoperative irradiation is recommended
based on the tumor stage, tumor histology, and surgical
findings after tumor resection. One of them was treated
with adjuvant radiotherapy with a total tumor dose of 66
Gy in 33 daily fractions after operation – excision of the
primary tumor and the unilateral neck dissection (Fig-
ure 2.). Higher doses of radiation (>60 Gy) are required
for microscopic disease to decrease the chances of loco-
regional failure because of interruption of the normal
vasculature, scarring, and relative hypoxia in the tumor
bed. The other patient was treated with primary radio-
therapy (RT) after a tumor biopsy with a total tumor
dose of 70 Gy in 35 daily fractions, with 2 opposite lateral
field and one direct field to the neck, because he wanted
to be treated with radiotherapy only19,21.
Two patients had an adenocarcinoma of the prostate
T2 N0 M0, Gleason score 6 and PSA 10 ng/mL (Stage II).
The combination of the Gleason score, PSA level and
stage can effectively stratify patients into categories as-
sociated with different probabilities of achieving a recov-
ery. The primary treatment options for initial therapy for
localized prostate cancer includes radical prostatectomy
or radiotherapy19,22. After prostate biopsy our patients
were treated with primary curative radiotherapy with a
total tumor dose of 70 Gy in 35 daily fractions with 4 ra-
diotherapy fields.
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Fig. 1. Example for irradiation of the chest wall and regional lymphatic portal.
Fig. 2. Carcinoma of the oropharynx – lateral and anterior por-
tals for treating patient with primary tumor and cervical lymph
nodes.
One patient was diagnosed with endometrial cancer
G3 stage IIIA. This form of cancer is usualy treated with
pelvic RT with or without vaginal brachytherapy, whole
abdominopelvic radiotherapy19,23. Our patient was treat-
ed with pelvic RT 50 Gy in 25 daily fractions with 2 oppo-
site fields and with vaginal brachytherapy.
One patient was diagnosed with partial operabile
patohistology brain meningioma. Meningioma is a be-
nign tumor, usually with a well-defined plane separating
them from the surrounding brain parenchyma. In gen-
eral, total extirpation is the therapy of choice. But subto-
tal resection or recccurent tumor needs to be treated
with radiotherapy19,24. Our patient was treated with frac-
tionated external beam radaition therapy – 2 opposite
fields to include tumor volume and the free margins with
total tumor dose 60 Gy in 30 daily fractions.
One patient was diagnosed with unresectabile non-
-small cell lung cancer T4N0M0 (stage IIIB). This form
of cancer is usualy treated with radiotherapy + che-
motherapy19,25. Our patient was treated with radiother-
apy because chemotherapy is contraindicated (cardiovas-
cular disease). Radiotherapy after tumor biopsy with
total tumor dose of 66 Gy in 33 daily fractions was ap-
plied in the primary tumor and regional lymph nodes.
One patient was diagnosed with seminoma. Early
stage seminoma is a radiosensitive tumor. Between 15%
and 20% of seminoma patients stage I, relapse during
surveillance if they do not receive adjuvant radiation
therapy after orchiectomy. The median time to relapse is
approximately 12 months, but relapses do occur more
than 5 years following. Patients with disease in stages IA,
IB, and IS are treated with radiation (25–30 Gy) to the
infradiaphragmatic area including para- aortic lymph
nodes19,26. Our patient was treated with 25Gy in 16 daily
fractions (Figure 3).
Blood sampling
Blood sampling was made by venepuncture; a way of
acquisition usually accepted as non-traumatic for pa-
tients. Further laboratory handlings with blood samples
and all investigations have been carried out in accor-
dance with a high standard of ethics.
Samples of venous blood (5 ml) were collected in
heparinized vacutainer tubes (Becton Dickinson, N.J.,
USA) under sterile conditions. The current study used
each cancer patient as his / her own control. Altogether
four blood samples were collected from each donor. Pre-
-treatment blood sample (I) was collected on day 1 of the
first radiotherapy cycle, two hours prior to the irradiation.
Response of peripheral blood leukocytes to the radiother-
apy was evaluated on blood sample taken within two
hours after the application of the first dose (II), as well as
in the middle of the radiotherapy cycle (III) and within 2
hours after the last received radiotherapy dose (IV).
All blood samples were handled in the same manner.
After venepuncture, they were coded, cooled at +4oC in
the dark and transferred in laboratory. They were pro-
cessed immediately after transportation (within a maxi-
mum of one-hour period after collection) by means of the
alkaline comet assay.
The alkaline comet assay
All chemicals were purchased from Sigma Chemicals
(St. Louis, MO, USA). The comet assay was carried out
under alkaline conditions, basically as described by
Singh et al.27. Fully frosted slides were covered with 1 %
normal melting point (NMP) agarose. After solidifica-
tion, the gel was scraped off from the slide. The slides
were then coated with 0.6 % NMP agarose. When this
layer had solidified a second layer containing the whole
blood sample (4 µl) mixed with 0.5 % low melting point
(LMP) agarose was placed on the slides. After 10 minutes
of solidification on ice, slides were covered with 0.5 %
LMP agarose. Afterwards the slides were immersed for 1
h in ice-cold freshly prepared lysis solution (2.5 M NaCl,
100 mM Na2EDTA, 10 mM Tris-HCl, 1 % Na-sarcosinate,
pH 10) with 1 % Triton X-100 and 10 % dimethyl sul-
foxide added fresh to lyse cells and allow DNA unfolding.
The slides were then randomly placed side by side in the
horizontal gel-electrophoresis tank, facing the anode.
The unit was filled with freshly prepared electrophoretic
buffer (300 mM NaOH, 1 mM Na2EDTA, pH 13.0) and
the slides were set in this alkaline buffer for 20 min to al-
low DNA unwinding and expression of alkali-labile sites.
Denaturation and electrophoresis were performed at 4oC
under dim light. Electrophoresis was carried out for the
next 20 min at 25 V (300 mA). After electrophoresis the
slides were washed gently three times at 5-min intervals
with a neutralisation buffer (0.4 M Tris-HCl, pH 7.5) to
remove excess alkali and detergents. Each slide was
stained with ethidium bromide (20mg/ml) and covered
with a coverslip. Slides were stored at 4oC in humidified
sealed containers until analysis.
To prevent additional DNA damage, handling with
blood samples and all steps included in the preparation of
slides for the comet analysis were conducted under yel-
low light or in the dark. Furthermore, to avoid possible
position effects during electrophoresis two parallel repli-
cate slides per sample were prepared. Each replicate was
processed in a different electrophoretic run.
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Fig. 3. Example of paraaortic and pelvic irradiation portals for
treatment testicular seminoma.
Slides were examined at 250x magnification using a
fluorescence microscope (Zeiss, Germany), equipped with
an excitation filter of 515–560 nm and a barrier filter of
590 nm. Microscope was connected through a black and
white camera to a computer-based image analysis system
(Comet Assay II, Perceptive Instruments Ltd., U.K.).
Comets were randomly captured at a constant depth of
the gel, avoiding the edges of the gel, occasional dead
cells and superimposed comets. A total of 100 comets per
subject were scored (50 from each of two replicate slides).
As a measure of DNA damage in this paper tail length
(calculated from the midpoint of the head and presented
in micrometers) and tail moment were used.
Statistics
Statistical analyses were carried out using Statistica
5.5 software (StatSoft, Tulsa, USA). Each subject was
characterized for the extent of DNA damage by consider-
ing the mean (± standard error of the mean), median
and range for the comet tail lengths / moments mea-
sured. In order to normalize distribution and to equalize
the variances, a logarithmic transformation of data was
applied. Differences between comet parameters measur-
ed in individual blood samples were compared using a
t-test for dependent samples. The level of statistical sig-
nificance was set at p<0.05.
Results
Using a computer-based image analysis system, we
measured DNA migration in peripheral blood leukocytes
from cancer patients before and after radiotherapy. Indi-
vidual data on DNA damage recorded in peripheral blood
leukocytes are reported in Table 2. Box and whisker plots
on Figure 4 show the distribution of the comet tail length
values measured in individual patients.
The baseline DNA damage in peripheral
blood leukocytes
The results indicate inter-individual differences in
background, pre-therapy DNA damage in peripheral blo-
od leukocytes of cancer patients (samples I), considering
the two main parameters of the alkaline comet assay. As
indicated in Table 2, DNA migration was in range from
15.73±0.19 mm (patient No. 2, with breast carcinoma) to
37.85±3.12 mm (patient no. 9, with lung cancer). Corre-
sponding tail moment values were in range 13.11±0.19
to 34.11±2.97. Range (min.–max.) of the tail lengths
measured among cancer patients was 10.90 to 117.31
mm, and range of the tail moments was 8.89 to 113.12
(Table 2). The majority of differences in pre-therapy
DNA damage levels may be explained with different
life-style factors as well as different sensitivity to diag-
nostic treatment prior to the operation and radiotherapy.
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Fig. 4. Individual results of the alkaline comet assay on peripheral blood leukocytes of cancer patients (numbered as 1–10) before (sam-
ple I) and after administration of radiotherapy (samples II–IV). Box and whisker plots showing the distribution of the comet tail length
values measured. DNA migration was evaluated on 100 comets per sample and expressed in micrometers.
Post-irradiation DNA damage in peripheral
blood leukocytes
The assessment of two comet parameters in blood
samples collected after administration of the first frac-
tion of radiotherapy (samples II) confirmed a strong posi-
tive response to the therapy (p<0.05, t-test for depend-
ent samples) in almost all patients. Exceptions were
patients No. 1, 3, 4 and 10 (Table 2). Among the patients
studied considerable interindividual differences were ob-
served. These differences reflect the impact of radiation
doses applied, but also indicating different susceptibility
and genome sensitivity. DNA migration was in range
from 18.56±0.58 mm (patient No. 2, with breast carci-
noma) to 60.30±2.17 mm (patient no. 7, with endometrial
carcinoma). Corresponding tail moment values were in
range 15.69±0.56 to 54.82±2.12. Range (min.–max.) of
the tail lengths measured among cancer patients was
12.18 to 117.31 mm, and range of the tail moments was
9.65 to 108.46 (Table 2).
Specific patterns of DNA damage were recorded in
blood samples analysed in the middle of radiotherapy cy-
cle (samples III). In majority of the patients studied, a de-
crease of DNA damage as compared to samples II were
observed. Exceptions were patients No. 1 and 3, in whose
blood samples significant increase of DNA damage was
observed (Table 2). Among the patients studied consider-
able interindividual differences were also observed. DNA
migration was in range from 16.36±0.24 mm (patient No.
5, with adenocarcinoma of the prostate) to 43.950±1.67
mm (patient no. 7, with endometrial carcinoma). Corre-
sponding tail moment values were in range 13.87±0.23
to 39.99 ± 1.64. Range (min.–max.) of the tail lengths
measured among cancer patients was 10.99 to 110.25
mm, and range of the tail moments was 7.58 to 103.01
(Table 2).
The values of both comet parameters recorded in
most of the blood samples collected after administration
of the last fraction of radiotherapy (samples IV) indicate
the possibility of the adaptive response. Namely, they did
not substantially differ, or were even lower as compared
to the pre-therapy values; exceptions were patients No.
1, 2, 6 and 10 (Table 2). DNA migration was in range
from 17.48±0.25 mm (patient No. 7, with patient no. 7,
with endometrial carcinoma) to 31.17±1.98 mm (patient
no. 2, breast carcinoma). Corresponding tail moment val-
ues were in range 14.94±0.25 to 27.18±1.80. Range
(min.–max.) of the tail lengths measured among cancer
patients was 12.18 to 98.72 mm, and range of the tail mo-
ments was 9.87 to 92.92 (Table 2).
The results obtained indicate that radiotherapy is ac-
companied by significant DNA damage in peripheral
blood leukocytes. Both parameters measured by the alka-
line comet assay are sensitive indicators of the individual
response to radiation treatment, and point to the individ-
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TABLE 1







Medical exposures Diagnosis TNM or stage Radiotherapy
1 F, 79 N
_
mam; chest and bone X breast carcinoma T2N1M0 45 Gy / 18 fr.
2 F, 76 N
_
mam; chest and bone X breast carcinoma T2N1M0 45 Gy / 18 fr.
3 M, 56 S
+
chest X carcinoma of the
oropharynx
T2N1M0 70 Gy / 35 fr.
4 M, 54 S
+
chest X carcinoma of the
oropharynx
T2N1M0 66 Gy / 33 fr.
5 M, 67 N
_




T2N0M0 70 Gy / 35 fr.
6 M, 70 N
_




T2N0M0 70 Gy / 35 fr.
7 F, 70 N
_
Chest X endometrial cancer Stage IIIA 50 Gy / 25 fr.tt.
10 Gy / 1 fr.bt.
8 F, 69 N
_
CT brain brain meningeoma benign tumor 60 Gy / 30 fr.
9 M, 66 S
_
Chest X end CT lung cancer T4N0M0 66 Gy / 33 fr.
10 M, 35 S
_
Chest X CT abd seminoma T1N0M0 25 Gy / 16 fr.
F – female; M – male; S – smoker; N – nonsmoker; TNM – Tumor Nodes Metastasis classification (NCCN 2005); T1 tumor size < 2 cm,
T2 between 2 and 5 cm, T3 > 5 cm and T4 tumor of any size with direct extension to chest wall or skin; N – nodes metastasis; N0 ab-
sence, N1 presence of nodes metastasis; M – metastasis; M0 absence, M1 presence of metastasis; fr – fraction; tt – teleradiotherapy; bt
– brachytherapy.
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TABLE 2









DNA migration – tail length (mm) Tail moment
Mean±SE Min. Max. Med. Mean±SE Min. Max. Med.
1 I 0 22.89±0.72 12.82 57.05 21.15 19.53±0.65 10.33 50.71 18.15
II 2.5 23.44±0.90 14.74 82.05 21.47 20.28±0.82 11.94 73.16 18.31
III 22..5 38.41±2.08b 14.74 97.43 28.53 33.80±1.92b 12.23 92.14 24.74
IV 45 26.64±1.05c 17.31 98.72 23.72 23.10±0.99c 14.16 92.92 20.47
2 I 0 15.73±0.19 10.90 20.51 15.38 13.11±0.19 8.89 17.82 13.05
II 2.5 18.56±0.58a 12.18 49.36 17.31 15.69±0.56a 9.65 45.29 14.20
III 22..5 18.15±1.06 10.90 67.95 14.74 15.14±1.00 7.58 63.08 11.95
IV 45 31.17±1.98c 12.82 94.87 22.11 27.18±1.80c 10.40 81.27 19.14
3 I 0 21.40±0.50 12.82 35.90 19.87 18.02±0.45 9.85 31.05 16.70
II 2 21.71±0.71 12.82 51.92 19.23 18.52±0.66 10.10 46.47 16.61
III 34 19.24±0.42 12.82 33.97 18.59 16.49±0.39 10.41 26.85 15.66
IV 70 21.83±0.80 14.74 62.18 19.23 18.89±0.73 11.89 54.76 16.72
4 I 0 23.08±0.74 13.46 51.28 21.15 19.99±0.70 10.92 46.03 18.32
II 2 23.22±0.83 14.10 60.26 20.51 20.10±0.78 11.34 56.23 17.78
III 34 37.89±2.01b 15.38 110.25 33.01 33.47±1.85b 12.48 103.01 28.75
IV 70 20.27±0.47c 14.74 42.31 19.23 17.55±0.44c 11.99 38.81 16.36
5 I 0 24.25±1.39 12.82 91.66 19.87 21.08±1.25 9.81 83.82 17.26
II 2 32.94±2.28a 14.10 110.90 22.11 28.21±2.17a 11.44 104.92 19.31
III 34 16.36±0.24b 12.18 27.56 16.03 13.87±0.23b 8.03 24.06 13.70
IV 70 17.94±0.51 12.18 51.92 16.67 15.32±0.48c 9.87 47.20 14.37
6 I 0 21.03±0.41 11.54 30.77 20.51 17.87±0.38 9.22 26.59 17.32
II 2 36.90±1.27a 16.67 77.56 33.97 32.29±1.19 12.90 69.99 29.80
III 34 22.46±0.78b 12.82 60.26 20.51 19.36±0.73 9.73 55.31 17.96
IV 70 24.29±0.55c 15.38 48.08 23.72 21.19±0.52 12.67 43.50 20.47
7 I 0 35.36±1.46 14.10 98.72 32.37 30.52±1.38 11.93 88.75 28.17
II 2 60.30±2.17a 25.64 116.66 60.58 54.82±2.12a 21.21 110.54 54.78
III 26 43.95±1.67b 15.38 94.87 43.91 39.99±1.64b 12.56 90.19 39.59
IV 60 17.48±0.25c 13.46 26.92 17.31 14.94±0.25c 10.55 23.30 14.72
8 I 0 22.90±0.57 15.38 49.36 21.79 19.69±0.52 12.85 44.23 18.59
II 2 27.78±1.03a 16.67 70.51 24.36 24.33±0.97a 13.79 67.68 21.14
III 30 21.10±0.65b 14.10 63.46 19.87 18.45±0.59b 11.81 56.32 17.03
IV 60 19.50±0.63c 12.18 44.87 17.31 16.78±0.58c 9.67 39.45 14.88
9 I 0 37.85±3.12 14.74 117.31 22.44 34.11±2.97 12.57 113.12 19.41
II 2 40.47±2.80a 14.74 117.31 28.53 35.49±2.56a 11.72 108.46 23.89
III 32 18.72±0.48b 12.18 37.82 17.63 15.96±0.44b 10.05 33.43 15.02
IV 66 21.29±0.36c 15.38 35.90 20.51 18.56±0.34c 12.79 32.17 18.02
10 I 0 22.91±0.77 14.10 44.23 19.87 19.57±0.70 11.12 38.53 17.11
II 1.5 22.99±1.26 12.82 102.56 20.51 19.69±1.14 9.94 92.41 17.50
III 12.48 20.25±0.35 14.10 30.77 19.87 17.76±0.35 11.06 28.60 17.13
IV 26 27.69±1.50c 12.82 83.97 22.76 24.10±1.39c 10.49 46.81 19.66
100 comets per each sample were scored. F – female; M – male; SE – standard error of the mean; Med. – median; a – significantly differ-
ent as compared to the sample I; b – significantly different as compared to the sample II; c – significantly different as compared to the
sample III (p<0.05, t-test for dependent samples).
ual capacity for DNA repair of radiotherapy-induced
damage in non-tumor cells. Specific patterns of DNA
damage recorded in samples analyzed in the middle of ra-
diotherapy and after receiving the last dose indicate the
possibility of adaptive response in some patients. Fur-
thermore, diverse DNA damage patterns observed at the
end of the radiotherapy indicate that patients with dif-
ferent types of solid tumors considerably differ according
to the genome sensitivity.
Discussion
Radiotherapy constitutes a major part of the treat-
ment of cancer patients. It may be used as the primary
therapy, but often is combined with surgery and chemo-
therapy or hormone therapy. Since radiotherapy works
by damaging the DNA of cancer cells, therapeutic inter-
ventions lead to the unavoidably exposure of different
non-target cells in treated patient. Because only a pro-
portion of treated population will develop a secondary
cancer in the future, the biomonitoring of patients after
successful therapy becomes extremely important. The
main goal is to discover sensitive subpopulations of pa-
tients, often with inherited genome instability, which is a
prerequisite to the increased risk of secondary carci-
noma.
The most extensively used biomarkers for the assess-
ment of genotoxic and carcinogenic risks involve cyto-
genetic endpoints as chromosomal aberrations, sister
chromatid exchanges, and micronuclei in mitogen-stimu-
lated peripheral blood lymphocytes 28, 29. Most of them,
however, are limited with the need for the cell proliferation
in vitro, as DNA damage must be processed into microscop-
ically visible lesions 30. Using novel and more sensitive tech-
niques DNA damage could be estimated directly, in single
cells and without previous cultivation. Such a powerful
technique is the alkaline comet assay that becomes wi-
dely accepted as a new tool in the field of genetic toxicol-
ogy and clinical medicine during the last decade 15.
In the present study, the alkaline comet assay was ap-
plied for the evaluation of background and radiation-in-
duced DNA damage in cancer patients who were subjected
to radiotherapy after surgically removed solid tumors.
The results obtained indicate that radiotherapy is accom-
panied by significantly increased levels of primary DNA
damage in peripheral blood leukocytes, and consequently
in other non-target cells or tissues. These findings are in
agreement with reports of other authors who investi-
gated the impacts of radio- or chemotherapy on non-tar-
get cells in cancer patients2,3,31–33. Previous investiga-
tions have shown that following radiotherapy patients
show a wide variation in response of both tumor and nor-
mal tissues33. Similarly was observed in our study. Al-
though a significant proportion of this variation can be
attributed to treatment-related factors, such as dose
inhomogeneity, there is increased evidence showing that
the major factors determining these differences are re-
lated to intrinsic biological factors34. The assessment of
background DNA damage in patients involved in the
present study also confirmed this assumption. We found
out that pre-therapy levels of DNA damage in peripheral
blood leukocytes of cancer patients were substantially
different. In some patients DNA damage was comparable
with 'normal’ values recorded among healthy population,
while in other it was notably increased, and even doubled
compared to controls. Since the DNA damage detected by
the alkaline comet assay represents a steady state be-
tween induction of lesions and their repair, lower damage
level in an individual may be the result of an actually
lower number of lesions or of a high efficiency of repair.
One part of the inter-individual variation is certainly re-
lated to age and some life-style factors (especially smok-
ing habits and alcohol consumption), as well as their pre-
vious medical, i.e. diagnostic, exposures 5, 35-37, while the
other part is related to inherited biological factors. The
observed diversity in background DNA damage among
cancer patients was difficult to explain, because they suf-
fered from different solid tumors. However, many au-
thors who applied the alkaline comet assay in biomo-
nitoring of cancer patients reported similar results and
found that the presence of malignant tumors itself
caused significantly increased levels of DNA damage as
compared to healthy population11–13.
As observed in our study, radiotherapy critically influ-
enced the levels of DNA damage in cancer patients, as de-
tected by the alkaline comet assay. It was not surprising,
because ionizing radiation causes a wide variety of DNA
damage, ranging from single- and double-strand breaks
in DNA, as well as DNA base modifications, oxidative
damage and alkali-labile lesions that can be easily con-
verted into strand breaks during alkaline denaturation
and therefore sensitively detected17,38,39. It is well known
that, besides direct ionization of DNA, ionizing radiation
also causes an indirect ionization when free radicals,
formed as a result of the ionization of oxygen, damage
the DNA. In the most common forms of radiation ther-
apy, the largest part of the radiation effect is through free
radicals. Ionizing radiation deposits energy that injures
or destroys cells in the area being treated (the »target tis-
sue«) by damaging their genetic material, making it im-
possible for these cells to continue to grow. Although ra-
diation damages both cancer cells and normal cells, the
latter are able to repair them and function properly.
Small frequent doses of radiation allow healthy cells time
to grow back, repairing damage inflicted by the radia-
tion. On the other hand, cancer cells generally are undif-
ferentiated and often have a diminished ability to repair
sub-lethal damage compared to most healthy differenti-
ated cells. Consequently, cells with inherited or accumu-
lated DNA damage will die or reproduce more slowly. For
these reasons, radiation therapy is usually given daily.
The dose delivered depends primarily on tumor type, but
also on many other factors such as whether radiation is
given alone or with chemotherapy, before or after sur-
gery, the success of surgery and its findings and many
other reasons. The typical dose for a solid epithelial tu-
mor may range from 50 to 70 grays (Gy) or more, while
lymphomas might receive doses closer to 20 to 40 Gy
given in daily doses that in adults typically are 1.8 to 2
Gy per fraction40.
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We observed that prolonged exposure to ionizing radi-
ation during the course of radiotherapy leads to the some
kind of adaptive response in peripheral blood leukocytes
in majority of treated patients. Other authors also re-
ported the same phenomenon. Small acute single doses
of ionizing radiation produce damages in a very short
time. Many of these are double-strand breaks of the
DNA. Under normal conditions cells have to cope with al-
most 106 damages due to reactive oxygen species pro-
duced by normal metabolic activity41,42. The DNA double
strand breaks induced by the acute, low radiation dose
may be sufficient to activate induced resistance, which
may protect cells even against damage due to metabo-
lism. The adaptation induced by low doses of radiation is
attributed to the induction of a novel efficient chromo-
some break repair mechanism that if active at the time of
challenge with high doses would lead to less residual
damage43. Previous investigations also indicate that the
human population exhibits heterogeneity in the adaptive
response to ionizing radiations that might be, at least in
part, genetically determined44. The results of our study
are also in agreement with these observations.
Regardless of the benefits of radiotherapy, therapeu-
tic exposure to ionizing radiation may also lead to the in-
duction of secondary cancers in the treated area. In order
to spare interstitial tissue (such as skin or organs which
radiation must pass through in order to treat the tumor)
several angles of exposure are utilized such that the radi-
ation beams overlap on top of each other at the tumor,
providing a much larger absorbed dose there than in the
surrounding, healthy tissue40.
The presence of significantly increased levels of DNA
damage, as caused by ionizing radiation, is ‘desirable’ in
cancer cells, but not in other non-target cells. Although
the majority of lesions induced by ionizing radiation are
successfully repaired in relatively short time after expo-
sure27,45, a part of DNA damage still remains unrepaired.
The most cytotoxic lesions are double-strand breaks
(DSBs). It is now accepted that misrepaired DSBs are the
principle lesions of importance in the induction of both
chromosomal abnormalities and gene mutations39,42. If
unrepaired DNA damage persisted in non-cancer cells
over long periods of time, it presents an increased risk for
development of secondary cancers.
Early detection of repair-deficient patients may pro-
vide arguments for stricter follow-up and prevention in
the management of many human cancers. Sensitive tech-
niques, as the alkaline comet assay employed in the pres-
ent study, may help in detection of genotoxic effects in-
duced in vivo by radiotherapy. Nevertheless, taking into
account the high variability found between and within
individuals, further knowledge of the fundamental as-
pects of the comet assay and on the kinetics of formation
and disappearance of comets after patient radiation ex-
posure in vivo are needed.
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PRIMJENA ALKALNOG KOMET-TESTA U PROCJENI O[TE]ENJA DNA
U BOLESNIKA LIJE^ENIH RADIOTERAPIJOM
S A @ E T A K
Istra`ene su razine primarnih o{te}enja izazvane radioterapijskim lije~enjem u DNA ne-tumorskih stanica boles-
nika s novotvorinama te je procijenjena dinamika njihova popravka. Istra`ivanjem je obuhva}ena skupina bolesnika s
razli~itim solidnim tumorima koji su lije~eni radioterapijom. Razine primarnih o{te}enja DNA u leukocitima periferne
krvi procjenjivane su s pomo}u alkalnog komet-testa. Analizirani su uzorci krvi izuzeti: prije i nakon primjene prve
doze zra~enja, u sredini ciklusa radioterapije te nakon primitka posljednje doze zra~enja u ciklusu. Rezultati istra`i-
vanja upu}uju na zna~ajno povi{ene razine o{te}enja DNA u usporedbi s njihovim osnovnim vrijednostima u gotovo
svih bolesnika nakon primitka prve doze zra~enja. U uzorcima analiziranim sredinom te po zavr{etku ciklusa radio-
terapije uo~eni su specifi~ni obrasci o{te}enja DNA koji ukazuju na mogu}i adaptivni odgovor u nekih bolesnika. Dobi-
veni rezultati upu}uju na postojanost o{te}enja u DNA leukocita periferne krvi bolesnika s novotvorinama (a mogu}e i
u drugim ne-tumorskim stanicama) nakon zavr{enog zra~enja, koji su sna`ni predskazatelji rizika od pojave sekundar-
nih novotvorina. Nadalje, potvr|ena je primjenjivost komet-testa kao osjetljivog i brzog testa za procjenu o{te}enja
genoma nakon ozra~ivanja u uvjetima in vivo.
